All-trans retinoic acid (RA) has been successfully used in the treatment of patients with acute promyelocytic leukemia (APL). It induces differentiation of APL cells and reduces the bleeding tendency in APL patients. It has been proposed that plasminogen activation could affect the fibrinolytic balance in patients with leukemia. In our earlier study we found that treatment of APL cells with RA results in changes in urokinase (uPA) production. As interferons (IFNs) and dexamethasone can be used together with RA in the treatment of patients with APL, we have now studied the effects of RA together with IFNs and dexamethasone on the plasminogen activation cascade of these cells, including measurement of plasmin generation and uPA receptor (uPAR), using enzyme immunoassays, fluorescence-activated cell sorter analysis and RNA extraction with Northern blotting. Our main results were: (1) plasmin was formed on the surface of APL cells; (2) RA stimulated transiently plasmin generation and increased uPAR mRNA level; (3) IFNs ␣ and ␥ potentiated RA in its effects on uPA and plasmin activities and on uPAR level; (4) dexamethasone suppressed totally the effect of RA on uPA induction and plasminogen activation; and (5) IFNs and dexamethasone alone did not have potent effects on plasminogen activation. These results may assist in the design of therapy for APL patients.
Introduction
Malignant cells are known to secrete plasminogen activators (PAs):
1,2 urokinase (uPA) and tissue-type plasminogen activator (tPA). uPA activity has been related to tumor cell invasion and cell migration 1,2 whereas tPA is associated with intravascular fibrinolysis. 3 uPA bound to the cell surface through a specific receptor [4] [5] [6] [7] activates cell-bound plasminogen. 8, 9 In this way plasminogen activation on the cell surface along with other tissue-destructive enzymes facilitates migration and invasion of malignant cells through the extracellular matrix. 10 The role of uPA and plasminogen activation in malignancy is reinforced in many studies, in which high levels of uPA and its inhibitor PAI-1 have been detected in different tumors. 11 Plasminogen activation in leukemia cells has been less well characterized. 2 However, patients with leukemia have symptoms such as bleeding tendency and infiltration of leukemic cells to other organs, 12 processes in which plasminogen activation could be involved. A number of studies indicate that PAs, especially uPA, are expressed in excess by malignant leukemia cells. In myeloid cells isolated from leukemia patients both uPA and tPA have been detected. 13 Mainly uPA activity was found on the surface of leukemic cells studied ex vivo from patients with acute leukemia 14 In contrast, the surface of the mononuclear cells isolated from the peripheral blood of patients with chronic leukemia and healthy persons was found to be negative for uPA. Similar results have been obtained in analysis of leukemia cell lysates from patients with acute leukemia. 15 Also, the onset of blast crisis in chronic myeloid leukemia (CML) has been correlated with an induction of uPA in CML cells. 15 The receptor for uPA (uPAR) has been detected on the surface of leukemic cells isolated from patients with myeloid leukemia. 16 Furthermore, uPAR has been characterized as an activation antigen for monocytes and its expression is increased also in activated T lymphocytes. 17 It has also been proposed that PAs play an important role in the tissue invasion by lymphoblastic T cells. 18 In addition to blood leukocytes, high tPA and uPA activities have been detected in cerebrospinal fluid samples of leukemia patients. 19 Acute promyelocytic leukemia (APL) is a form of myeloid leukemia, in which leukemic cells carry a specific chromosomal translocation t (15;17) . [20] [21] [22] The translocation breakpoint is in the middle of the gene for the nuclear retinoic acid receptor ␣ (RAR␣). Patients with APL were previously treated with various chemotherapeutic agents, but currently all-trans retinoic acid treatment is the most efficient and popular treatment. 21, 22 RA is an active metabolite of vitamin A. It induces the differentiation of APL cells both in vitro and in vivo. 23, 24 Patients with APL are prone to disorders of coagulation and bleeding, especially at the induction of remission. They have serious episodes of bleeding associated with disseminated intravascular coagulation (DIC). 12 The initial trigger of this syndrome is not known but it has been suggested that the actual problem in DIC is excessive fibrinolysis rather than excessive coagulation and possibly plasminogen activation takes part in that syndrome. 25, 26 Reduced plasma levels of PAI-1, increased levels of plasmin-␣ 2 -antiplasmin complexes, hypofibrinogenemia have been detected in APL patients with DIC syndrome. 25, [27] [28] [29] In clinical use it has been noticed that RA treatment reduces the bleeding tendency in APL patients. 25, 30 It has also been proposed in other types of leukemias that plasminogen activation could affect the fibrinolytic balance. 2, 26, 31 The most difficult side-effects of RA therapy (hyperleukocytosis, fever and pulmonary infiltrates of leukemic cells) have been designated as retinoic acid syndrome (RA syndrome). 32 The onset of this syndrome usually occurs 2-21 days after the start of RA treatment and can have a fatal outcome. A rapid mobilization of leukemic cells to various organs is detected at the onset of this syndrome. These sideeffects have been reported to be relieved by dexamethasone.
Interferons (INFs) are cytokines with antiproliferative, antiviral and immunomodulatory functions. Recent studies have suggested that RA and IFNs have synergistic effects on cellular differentiation. 33, 34 They have been used as a combination therapy with encouraging results, in certain forms of cancer such as squamous cell carcinoma of the skin and cervix. 35 Whether such combination therapy has potential in other cancers is not known. Results obtained by in vitro studies have suggested that IFNs could overcome retinoid resistance, which There are some clinical studies concerning IFNs in APL treatment. 37, 38 In one study IFN-␣ was used as treatment in chronic phase in a patient with APL. It has also been shown that clinical and cytogenetic remission is attainable after an early relapse of APL by combining IFN-␣ with RA treatment. 38 In our earlier work we found that treatment of APL cells with RA results in changes in uPA production. 39 Since IFNs and dexamethasone can be used together with RA at the induction of remission in patients with APL, in the present work we studied the effects of RA together with IFNs and dexamethasone to the plasminogen activation cascade. We used the NB4 cell line 40 which has been established from a blood sample of a patient with APL during relaptic phase. We studied the induction of different contributory factors of the plasminogen activation system, namely uPA, its receptor uPAR and inhibitor PAI-1. We observed that plasminogen was activated and plasmin was generated on the surface of APL cells in accord with simultaneous expression and activity of uPA followed by induction of its receptor and inhibitors.
Materials and methods

Cell culture
The promyelocytic NB4 cell line was kindly provided by Dr Michel Lanotte (INSERM, Paris, France). 40 It was derived from the bone marrow of an APL patient during a relaptic phase and carries the chromosomal translocation t(15;17) characteristic of promyelocytic APL cells. The cells were grown in RPMI-1640 in the presence of 10% fetal calf serum (FCS) (GIBCO, Grand Island, NY, USA) containing 2 mmol/l glutamine, 100 IU/ml penicillin and 100 g/ml streptomycin. For enzymatic studies, the cells were washed twice with Dulbecco's balanced salt solution containing 0.2% BSA (DBSA) and suspended in growth medium containing plasminogendepleted FCS. Next morning the cells were centrifuged and suspended in fresh plasminogen-depleted growth medium at a density of 10 6 cells/ml. Duplicate samples of conditioned cell culture medium and of cell-bound uPA were collected at defined time-points after the addition of effectors to the cell cultures.
To determine the amount of cell-bound uPA activity the cells were first washed twice with DBSA and then eluted with acid glycine (20 mM glycine, 100 mM NaCl, pH 3.0). 41 The acid glycine fraction was neutralized with 1 M Tris-HCl, pH 8.0. Identically treated samples of cells were used to determine the cell-bound uPA and capacity to bind and activate plasminogen. To determine the capacity to activate exogenously added plasminogen to plasmin, the cells were suspended in plasminogen-depleted growth medium and human plasminogen (50 g/ml) was added. 42 Plasminogen was purified from precleared plasma according to Deutsch and Mertz. 43 Plasmin generation was allowed to proceed for 30 min at 37°C after which cells were washed twice with DBSA. Cells without incubation with plasminogen were used as negative controls. Cell-bound plasmin was eluted with 10 mM tranexamic acid (Kabi Pharmacia, Stockholm, Sweden) in DBSA (200 l per 10 6 cells) for 10 min at room temperature. The eluates were ready for enzymatic assays. Effectors 13-trans retinoic acid (Tretinoin) was kindly provided by F Hoffman-La Roche Ltd, Basel, Switzerland. The stock solutions were dissolved in ethanol and the concentration used in cell cultures was 1 M. Interferons ␣ and ␥ were a kind gift from Drs Kari Cantell and Ilkka Julkunen of the National Public Health Institute, Helsinki, Finland. 44, 45 They were dissolved in RPMI-1640 and the concentration used in cell cultures was 1000 IU/ml. Dexamethasone (Sigma, St Louis, MO, USA; D8893) was dissolved in ethanol and the concentration used was 100 nM.
Immunocapture assay for plasminogen activators uPA and tPA activities were assayed by a microimmunocapture assay. 46 Briefly, samples were bound in duplicate or triplicate to microwell plates coated with rabbit IgG to human uPA (American Diagnostica, Greenwich, CT, USA; 389) or goat IgG to human tPA (American Diagnostic; 387). After binding, the wells were washed with PBS + 0.05% Tween 20 and then human plasminogen was added. Plasmin formed by antibodybound activators was measured by its thioesterase activity on Z-lysine thiobenzyl ester (Peninsula Laboratories, Belmont, CA, USA). The absorbances were read in a Labsystems Multiscan MCC/340 plate-reader at 405 nm. Standard dilutions of purified human urokinase (American Diagnostica; 124) and human tPA (American Diagnostica; 116) were used for quantitation of enzymatic activity (0-1.0 IU/ml). The absorbance curve was linear between values 0.1 and 1.0.
Assay of eluted plasmin
Eluted plasmin samples (50 l) were pipetted in duplicate in microwell plates and plasmin was measured by its thioesterase activity as described above for the immunocapture assay. 46 Standard dilutions of human plasmin (Kabi Diagnostica) were used for quantitation of enzymatic activity.
FACS (fluorescence activated cell sorter) analysis for uPA and its receptor (uPAR)
For FACS analysis the cell samples (1 × 10 6 cells/ml) were collected and the cell suspension was centrifuged for 10 min at 1000 g. The cells were washed with PBS containing 1 l FCS in 1 ml PBS (PBS-FCS) and resuspended after centrifugation in 50 l of antiserum. For detecting uPA either monoclonal mouse IgG clone 12 (a kind gift from Dr Keld Dano / , Finsen Laboratory, Copenhagen, Denmark) or polyclonal rabbit IgG (American Diagnostica; 389) were used at the concentration of 50 g/ml in PBS containing 10% FCS (dilution buffer). For detecting uPAR monoclonal IgG against uPAR (American Diagnostica; 3936) was used at the same concentration. Cells used as negative controls were suspended in the dilution buffer or treated with control IgG against cytokeratin (PKK2; Labsystems, Helsinki, Finland), which should not bind to NB4 cell surface. Negative cell controls included cells treated with all different effectors (RA, IFNs and dexamethasone). The cells were incubated in the presence of IgG for 30 min on ice after which the cells were washed twice with PBS-FCS and resuspended in 100 l of fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG or swine anti-rabbit IgG (DAKO, Copenhagen, Denmark) diluted 1:50 in dilution buffer. After 30 min on ice the cells were washed twice with PBS-FCS and resuspended in 300 l of PBS on ice. The analysis was made with FACScan (Becton Dickinson, Mountain View, CA, USA). The FACS analysis was made five times in the same set-up and similar kinds of result were obtained each time. In each analysis the samples were analyzed at the same time to obtain reliable and comparable results.
RNA extraction
For Northern blot analysis the cell samples (10 × 10 6 cells) were collected at various time-points (0, 10, 21 and 46 h). The RNA extraction was done according to the method of Chomczynski and Sacchi. 47 The cells were lysed in solution-D containing guanidium thiocyanate, sodium citrate, sarkosyl and 2-mercaptoethanol and the RNA-phase was separated with phenol and chloroform-isoamyl alcohol solution. The RNA isolated was quantitated with a spectrophotometer and the samples containing the same amount of mRNA (20 g) were size fractionated on 1% agarose gels and transferred to a Hybond N nylon membrane (Amersham, Bucks, UK). Prehybridizations and hybridizations were performed in a solution containing formamide, standard saline citrate (SSC), N-laurosyl sarkosine, sodium dodecyl sulfate (SDS) and blocking solution (Boehringer Mannheim, Mannheim, Germany). The hybridization was done overnight and after that filters were washed twice at 42°C with 0.5 × SSC and 0.5 × SDS and then twice at 68°C. The detection was done using alkaline phosphatase conjugated anti-digoxigenin (DIG) antibodies. Luminescent reactions from filters were exposed to X-ray films. The X-ray films were scanned and the relative intensities were determined in comparison with the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) signal from the same filter.
Molecular probes
The cDNA clone for uPA (fragment BamHI) 48 was obtained from the American Type Culture Collection (Rockville, MD, USA). The cDNA clones for the uPAR (fragment SphI SacI), 49 PAI-1 (fragment BamHI) 50 and GAPDH (fragment PstI) 51 were kindly provided by Dr Jens Eriksen (uPAR; Finsen Laboratory, Copenhagen, Denmark), and Dr Leif Lund (PAI-1; Finsen Laboratory). The probes were labeled with DIG coupled to dUTP by a DIG random-primed DNA labeling kit (Boehringer Mannheim; catalogue No. 1175 033) according to the manufacturer's instructions and applied on filters in hybridization mixture.
Expression of results
Unless otherwise indicated, mean values ± s.d. of triplicate measurements of supernatant and cell surface samples from duplicate cultures have been presented. In plasmin assays mean values of two separate experiments have been presented. Each experiment has been made several times (n Ͼ 10) and similar kinds of result have been obtained each time. Representatives of these experiments are presented in Figures 1-4 . The Student's t-test was used for the comparison of means. Results were considered significant when P р 0.05.
Results
Urokinase production and plasmin formation is transiently enhanced by RA Differentiation of NB4 cells was induced with 1 M RA and the conditioned medium and cell-bound uPA and plasmin were collected after 12-48 h of treatment. The uPA production increased markedly in 12 h and was usually maximal at 24 h. The effect of RA on the uPA activity was less pronounced on the cell surface (1.1 times higher, P Ͼ 0.05) than it was in the conditioned medium (13.6 times higher, P Ͻ 0.05). Both in the conditioned medium and on the cell surface the amount of uPA decreased below the level of control-treated cells in 48 h (Figure 1) . tPA was also assayed, but no active tPA was found. Exogenously added plasminogen was activated on the surface of both control and RA-treated cells. The amount of plasmin generated followed closely the curve of uPA and the highest amounts of plasmin were detected at the same time when uPA production was at its peak. At the 48 h time-point the control cells continued to generate plasmin, whereas in the RA-treated cells the plasmin production fell to the original level ( Figure 1 ).
Interferons enhance the effect of retinoic acid on uPA and plasmin production NB4 cells were stimulated with combinations of RA and IFNs or with RA or IFNs alone and the samples were collected at the same time-points as above. IFN-␥ increased the uPA activity on the cell surface in 24 h of treatment but otherwise interferons alone did not increase the uPA or plasmin activity compared to control-treated cells (Figure 1 ). In contrast, either IFN-␣ or ␥ together with RA increased uPA activity and plasmin formation more than RA alone and the increase was quite remarkable compared to the control (1.6 times on the cell surface and 25.2 times in the conditioned medium in 24 h with IFN-␥, P Ͻ 0.05). When used at the same concentrations the two IFNs seemed to have quite similar effects (only results for IFN-␥ are shown). As was the case with RA alone, the uPA activity and the amount of plasmin elutable from the cell surface increased up to 24 h and then decreased again in 48 h. In contrast, in the controls the amount of plasmin was still high after 48 h of treatment and in eluates of cells, which were treated with IFNs alone, the amount of plasmin was between the level in control-treated and RA-treated cells. In the eluates of cells, which were simultaneously treated with RA and IFNs, the amount of plasmin decreased below the control levels in 48 h (Figure 1) .
Dexamethasone blocks the effect of RA
Dexamethasone is an immunosuppressive glucocorticoid and is also used in the treatment of APL patients, when there are side-effects from RA. To study its effects, NB4 cells were treated with RA and dexamethasone together or RA alone. Dexamethasone was found to suppress significantly in 24 h of treatment the RA effect on uPA activity and the amount of uPA on the cell surface was even less than in the controls (P Ͻ 0.05). Plasmin formation on the cell surface was also reduced in 24 h after treatment with RA and dexamethasone. The difference between the combination of RA and dexamethasone and RA alone was significant (P Ͻ 0.05). It is note-
Figure 1
Urokinase activity in the conditioned medium and on the cell surface and plasmin activity on the surface of NB4 cells after treatment with RA and IFN-␥. The cells were treated with 1 M RA and 1000 IU/ml IFN-␥ or with either drug alone. Cell surface eluates and conditioned media were collected after 12-48 h of treatment. uPA activity was measured by an immunocapture assay and the amount of plasmin was determined as described in Materials and methods. The results are given in quantitative values; for uPA (IU/ml) and for plasmin (g/ml). Values for uPA are calculated as the mean values of triplicate measurements of supernatant and cell surface samples from duplicate cultures and those for plasmin are calculated as the mean values of two separate experiments. The error bars indicate the standard deviation of the measurement.
worthy that the amount of plasmin was diminished close to the control levels ( Figure 2 ). Dexamethasone alone also reduced the plasmin formation compared to controls ( Figure  2 ). The effect of dexamethasone was also controlled at other time-points and its effect was similar (results not shown). The effect of dexamethasone on the combination of RA and IFN-␥ was also studied and the effect was only slightly reduced (results not shown).
RA, interferons and dexamethasone have an effect on uPA and uPAR on the cell surface
The cell surface uPA and uPAR were detected by FACS analysis. In parallel with the increased uPA activity, RA increased the level of uPA antigen on the cell surface in 20 h (1.1-fold, P Ͼ 0.05) (Figure 3 ). RA together with IFN-␥ increased the amount of uPA more than RA alone (1.7-fold, P Ͻ 0.05). The same inhibitory effect of dexamethasone seen in the immunocapture assay in combination with RA (Figure 2 ), was detected on the cell surface uPA antigen by the FACS analysis ( Figure  3 ). It should be noted that the scale in FACS analysis is logarithmic, so the differences cannot be directly compared to those measured in immunocapture assays.
After 20 h of RA treatment there was less uPAR on RAtreated cells than in control-treated cells (results not shown). However, in 48 h the uPAR antigen level increased again to the control level (Figure 4) . When the cells were treated with IFN-␥ and RA together there was more uPAR on the cell surface than in control-treated cells already in 20 h (results not shown) and the increase was more noticeable in 48 h (1.5-fold higher than the control, P Ͼ 0.05) (Figure 4 ). IFN-␥ alone raised the amount of uPAR on the cell surface (1.3-fold, P Ͼ 0.05), but the increase was less than with RA and IFN-␥ together (Figure 4 ). Dexamethasone could not prevent uPAR antigen expression induced by RA. Together they had quite similar effects on uPAR as RA alone (Figure 4 ). Dexamethasone alone did not have a significant effect on cell-surface uPAR (not shown).
mRNA levels of uPA and uPAR Cells were treated with combinations of RA, IFNs and dexamethasone and were then collected as described in Materials and methods. RA increased uPAR mRNA only in 46 h (5.3-fold more than the control) ( Figure 5 ), so the increase was not yet seen in the protein level in 46 h. RA together with IFN-␥ increased uPAR mRNA already in 21 h (3.6-fold) and the increase was more notable in 46 h (4.3-fold). The same effect was also seen in FACS analysis in 46 h (Figures 4 and 5 ). Dexamethasone together with RA did not prevent the uPAR increase caused by RA in 46 h (4.6-fold). Dexamethasone or IFN-␥ alone did not have a significant effect on uPAR mRNA ( Figure 5 ).
RA increased uPA mRNA already transiently in 10 h (two times more than in the control) and started to decrease in 21 h. IFN-␥ together with RA potentiated the effect of RA (3.2-fold) and the decrease was seen later than with RA alone ( Figure 5 ). Dexamethasone together with RA slightly prevented the uPA increase and the effect was also seen with RA and IFN-␥ and dexamethasone together. Dexamethasone and IFN-␥ alone did not have effects on uPA mRNA compared to control. The uPA and uPAR mRNA results were in good agreement with the protein level data.
Figure 2
Urokinase activity in the conditioned medium and on the surface of NB4 cells and plasmin activity on the cell surface after treatment with RA and dexamethasone. The cells were treated with 1 M RA and 100 nM dexamethasone. The conditioned media and acid eluates were collected after 24 h of treatment. uPA activity was measured by an immunocapture assay and the amount of plasmin as described in Materials and methods. The results are given in quantitative values; for uPA (IU/ml) and for plasmin (g/ml). Values for uPA are calculated as the mean values of triplicate measurements of supernatant and cell surface samples from duplicate cultures and those for plasmin are calculated as the mean values of two separate experiments. The error bars indicate the standard deviation of the measurement.
PAI-1 mRNA level increases after uPA increase PAI-1, an inhibitor of uPA, increased after RA treatment in 46 h (4.2-fold more than the control) ( Figure 5 ). The increase was more notable with RA and dexamethasone together (9.6-fold) and with RA and IFN-␥ together (9.0-fold). Dexamethasone alone also slightly increased PAI-1 mRNA already in 10 h (1.4-fold) , but IFN-␥ alone did not have any effect compared to control ( Figure 5) .
All results from different methods and experiments are summarized in Table 1 .
Discussion
In the present work we wanted to see whether our earlier observed transient uPA increase after RA treatment results in plasmin generation and whether IFNs and dexamethasone together with RA have an effect on the plasminogen activation cascade. Firstly, our results show that IFNs potentiate RA in its effects on uPA, uPAR and PAI-1 induction and in plasmin activity and dexamethasone suppresses the effect of RA on uPA induction and plasminogen activation. Secondly, plasminogen is activated and plasmin is generated on the cell surface and it is in accord with simultaneous uPA activation. Finally, IFNs and dexamethasone alone do not have potent effects on the plasminogen activation cascade.
Our results indicate that simultaneously with transient uPA increase also exogenous plasminogen was activated on the cell surface and plasmin was generated. Plasmin formation is the ultimate outcome of the plasminogen activation system and with its potent protease activity plasmin could interfere the normal fibrinolytic balance and be a part of a cascade leading to excessive bleeding disorders encountered with APL patients. Our results also show that plasmin formation is markedly decreased in 48 h after RA treatment. This indicates that the overall outcome of RA treatment is a decrease in fibrinolytic activity, which fits well with the clinical experience showing that RA rapidly resolves the coagulation abnormalities in APL patients during RA treatment. 25 The results obtained with Northern blotting confirm the protein data. It seems that uPAR increase follows the uPA increase and these changes do not parallel each other; so the uPAR mRNA level is regulated through other slower mechanisms than uPA level is. uPAR increase may be associated with granulocytic differentiation and increase in cell adhesion properties. PAI-1 production may regulate uPA production as it was shown here that uPA mRNA started to decrease after PAI-1 increase.
Recent studies have suggested that RA and IFNs have synergistic effects on cellular differentiation. 33, 34 It has been shown that IFNs induce retinoic acid receptors in acute promyelocytic leukemia cells and cooperate with RA to overcome the resistance of cells to RA. 36, 52 Also RA activates interferon regulatory factor-1 gene expression in promyelocytic leukemia cells. 53 Our results suggest that IFNs together with RA potentiate the effect of RA on uPA and uPAR production and plasmin formation. The effect of IFNs together with RA was quite remarkable compared to the result that IFNs alone did not have a significant effect on plasminogen activation. Dexamethasone could not prevent the increase totally and it seemed that it only had an effect on the increase caused by RA. The assays of receptor-bound uPA by the immunocapture assay and FACS analysis were in agreement with one exception. IFNs alone had only a slight effect on the uPA production or Mean Median Mean Median plasmin formation. However, when IFN-␥ was used alone FACS analysis showed an increase in uPA antigen on the cell surface. In contrast, such a clear effect could not be seen in the cell-bound uPA activity at a comparable time-point. The reason for this discrepancy may be due to different forms of uPA they are measuring.
In clinical use the relapse of APL after a remission period induced by RA treatment occurs after a mean duration of 1 month to 2 years. 21 It is possible that RA together with IFNs could make this remission period longer due to better cellular differentiation. However, if plasmin formation is partly responsible for the bleeding tendency associated with APL, IFNs together with RA could increase these harmful effects because of more potent plasminogen activation.
uPA and uPAR expression have been associated with the motility and invasive capacity of myeloid cells. 5 Therefore, our observation that RA treatment induces a rapid peak in urokinase activity with simultaneous plasminogen activation and plasmin formation could in theory result in a rapid mobilization of leukemic cells from the bone marrow to the circulation and furthermore to other organs. These events would generate symptoms characteristic of the RA syndrome. A mediator of the uPA induction could be IL-1␤, which was recently shown to be induced by RA. 54 IL-1 in turn enhances the uPA production of myeloid cells. 55 It is noteworthy that dexamethasone, which prevents the RA syndrome and diminishes its symptoms, 23 decreased the effect of RA on uPA production and plasmin formation. The amount of uPA on the cell surface was decreased below the control level after 24 h of RA treatment. In short, dexamethasone together with RA prevented the transient increase in uPA production and plasmin formation on cell surface and therefore Results are given as + (++, +++) or −. The effects of RA, IFN-␥ and dexamethasone are compared to control. An increasing number of + characters means progressive increase compared to control as well as − means decrease compared to control. Note that the time-points in the mRNA assays ( Figure 5 ) differ slightly from those used in the protein assays and given here.
stabilized fibrinolytic activity. Surprisingly, IFN-␥ or dexamethasone alone had little or no effect on uPA, PAI-1 or uPAR. An earlier study indicated that IFN-␥ could alone increase uPA activity in monocytoid cells 56 but our results show that in promyelocytic leukemia cells IFNs cooperate with RA responsive elements to induce plasminogen activation.
